ClinicalTrials.gg
CompletedNCT06605885PRESENTIIUpdated Oct 20, 2026

An Observational, Prospective, Multicenter Study to Evaluate the Biologic Use and Outcomes in Chinese Asthma Patients

An observational study in Asthma, sponsored by AstraZeneca. Completed at 29 sites in China. Per ClinicalTrials.gov, last updated 2026-10-20.

Sponsored by AstraZeneca · Observational

How we know

Updated Oct 20, 2026Now CompletedPrimary completion moved+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Case-only
Time perspective
Prospective
Enrollment
202
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 359 studies in Asthma by AstraZeneca — 19 open to participants now, 28 under way, 8 of them phase 3. Asthma · AstraZeneca.

Enrollment
89th of 110
202 · median 500
Started
2024
with 25 others
Observational
111 of 359
9 open now
Registered
333rd of 359
by date

Among the 359 studies in Asthma by AstraZeneca, this one is the 89th largest by enrollment of the 110 observational ones that give a count, is one of 26 that started in 2024, is one of 111 observational ones, and was the 333rd registered.

Asthma

4,850 studies on the registry are indexed under Asthma; 604 are open to participants now.

Browse Asthma studies →

Open to participants now

19 of the 359 studies in Asthma by AstraZeneca are open now, in 12 countries. Recruiting first, the newest first:

14 more — sign in →

By country, each count listing its studies:

All 19 open studies →

Who these studies take

Of the 416 Asthma studies recruiting now, 141 (34%) set no upper age limit and 204 (49%) stop at 75 or younger; 146 take children under 18; 105 take healthy volunteers.

This study: all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 359 studies in Asthma by AstraZeneca, or all of them as a file.
02

Study summary

This study is a multicenter, observational, prospective study to evaluate the asthma biologic use features and clinical outcomes in China. Patients will undergo clinical assessments and receive standard medical care as determined by the treating physician.

Read the detailed description

This study is a multicenter, observational, prospective study to evaluate the asthma biologic use features and clinical outcomes in China. Patients will undergo clinical assessments and receive standard medical care as determined by the treating physician.

Approximately 200 patients with a physician diagnosis of asthma and prescribed with asthma biologics at visit 1 will be enrolled in this study, distributed among 50 sites across different regions in China.

During the study period, patients will be identified consecutively and, if they meet eligibility criteria and provide informed consent will be entered into this observational study. Patients should have an asthma diagnosis and be prescribed at least once with biologics for asthma treatment at enrollment (Visit 1, Week 0).

After the enrollment, subjects will be followed up at Visit 2(Week 24) and Visit 3 (Week 52). V1, V2 and V3 will be followed up by on-site visit. At Visit 1, data within last 12 months will be retrospectively collected as baseline. Patients existing medical record (MR) data will be collected in week 24 and week 52. PROs (Asthma control test [ACT], Asthma Quality of Life Questionnaire (+12) [AQLQ(S)+12]) should be performed at Visit 1, Visit 2 and Visit 3.

No additional mandated interventions on top of routinely performed physician visits, examinations or treatments will be required. Patients will not receive any experimental disease management intervention or experimental treatment as a result of their participation in the study.

03

Conditions studied

  • Asthma

Browse trials for

04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

Approximately 200 asthma patients will be enrolled in this study distributed among 50 sites in China.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Chinese, Female or Male
  2. Age: no limitation
  3. Physician-confirmed asthma diagnosis with documented evidence of diagnosis or evidence of variable expiratory airflow limitation (e.g., from bronchodilator reversibility testing or other tests).
  4. Participants or their legal guardians must be able to provide .
  5. Prescription of asthma biologics at enrolment.

Exclusion criteria

Exclusion Criteria:

  1. Participation in an interventional study within the last 3 months.
  2. Any significant disease or disorder which, in the opinion of the investigator, may either put the patient at risk because of participation in the study with the usage of biologics, or may influence the results of the study, or the patient's ability to participate in the study
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Case-only
Time perspective
Prospective
Enrollment
202 participants (actual)
Patient registry
No
06

What researchers measure

Primary outcomes

  1. the proportion of days covered (PDC) with asthma biologics during 52 weeks

    to describe the persistence to asthma biologics using proportion of days covered (PDC) with asthma biologics during 52 weeks.

    Time frame: week52

Secondary outcomes

  1. Time from asthma onset to first biologic initiation(month)

    To describe asthma biologics treatment features

    Time frame: week0

  2. Duration (days) of treatment with different type of biologics.

    To describe asthma biologics treatment features

    Time frame: week 52

  3. Proportion of patients discontinued biologics in week 24 and week 52.

    To describe asthma biologics treatment features

    Time frame: week24,week52

  4. Proportion of participants switching to other biologics for asthma in week 24 and week 52.

    To describe asthma biologics treatment features

    Time frame: week24,week52

  5. Proportion of participants with concurrent used of multiple biologics in week 24 and week 52.

    To describe asthma biologics treatment features

    Time frame: week24,week52

  6. Proportion of different categories including anti-IL5, anti-IL5R, anti-IL4R, anti-IgE and anti-TSLP of biologics during 52 weeks

    To describe asthma biologics treatment features

    Time frame: week 52

  7. Proportion of patients experiencing asthma related hospitalizations during 52 weeks

    To describe effect of biologics on healthcare care resource utilization (HCRU)

    Time frame: week 52

  8. Cost of asthma related hospitalization during 52 weeks

    To describe effect of biologics on healthcare care resource utilization (HCRU)

    Time frame: week 52

  9. Days on asthma related sick leaves during 52 weeks

    To describe effect of biologics on healthcare care resource utilization (HCRU)

    Time frame: week 52

  10. Number of emergency visit during 52 weeks

    To describe effect of biologics on healthcare care resource utilization (HCRU)

    Time frame: week 52

  11. Annualized exacerbation rates over 52 weeks

    To describe clinical outcomes of biologics including lung function, exacerbation, symptom control and quality of life in two subgroups

    Time frame: week 52

  12. Change from baseline of FEV1 at week 24, 52

    To describe clinical outcomes of biologics including lung function, exacerbation, symptom control and quality of life in two subgroups

    Time frame: week0,week 24, week 52

  13. Change from baseline of ACT score at week 24, 52

    To describe clinical outcomes of biologics including lung function, exacerbation, symptom control and quality of life in two subgroups

    Time frame: week0,week 24,week52

  14. Change from baseline of AQLQ(S)+12 score at week 24, 52

    To describe clinical outcomes of biologics including lung function, exacerbation, symptom control and quality of life in two subgroups

    Time frame: week0,week24,week52

  15. Change of proportion of patients with high-dosage ICS from baseline to week 24,52

    To describe maintenance treatment change after biologic initiation in two subgroups

    Time frame: week0,week24,week52

  16. Change of proportion of patients with maintenance OCS from baseline to week 24,52

    To describe maintenance treatment change after biologic initiation in two subgroups

    Time frame: week0,week 24,Week 52

  17. Proportion of days covered (PDC) with maintenance medication at baseline (in last 3 months)

    To describe the characteristics including background therapy, biomarkers, asthma triggers and comorbidities of biologics treated asthma patients in two subgroups

    Time frame: week0

  18. Levels of bEOS at baseline

    To describe the characteristics including background therapy, biomarkers, asthma triggers and comorbidities of biologics treated asthma patients in two subgroups

    Time frame: week0

  19. Levels of FeNO at baseline

    To describe the characteristics including background therapy, biomarkers, asthma triggers and comorbidities of biologics treated asthma patients in two subgroups

    Time frame: week0

  20. Levels of IgE at baseline

    To describe the characteristics including background therapy, biomarkers, asthma triggers and comorbidities of biologics treated asthma patients in two subgroups

    Time frame: week0

Other outcomes

  1. Proportion of different reasons for biologics discontinuation

    To describe reasons for biologic discontinuation and switching, including asthma control, adverse event, cost or other more reasons.

    Time frame: week52

  2. Proportion of different reasons for biologics switching

    To describe reasons for biologic discontinuation and switching, including asthma control, adverse event, cost or other more reasons.

    Time frame: week52

  3. Incidence of all AEs and SAEs

    To describe reasons for biologic discontinuation and switching, including asthma control, adverse event, cost or other more reasons.

    Time frame: week52

07

Study locations

29 sites
  • Research Site
    Beijing, China
  • Research Site
    Changsha, China
  • Research Site
    Chengdu, China
  • Research Site
    Foshan, China
  • Research Site
    Fuzhou, China
  • Research Site
    Guangzhou, China
  • Research Site
    Hangzhou, China
  • Research Site
    Hefei, China
  • Research Site
    Jinan, China
  • Research Site
    Kunming, China
  • Research Site
    Nanchang, China
  • Research Site
    Nanjing, China
  • Research Site
    Ningbo, China
  • Research Site
    Qingdao, China
  • Research Site
    Quanzhou, China
  • Research Site
    Shanghai, China
  • Research Site
    Shenyang, China
  • Research Site
    Shenzhen, China
  • Research Site
    Shijiazhuang, China
  • Research Site
    Suining, China
  • Research Site
    Taiyuan, China
  • Research Site
    Tianjin, China
  • Research Site
    Ürümqi, China
  • Research Site
    Wenzhou, China
  • Research Site
    Wuhan, China
  • Research Site
    Wuxi, China
  • Research Site
    Xi'an, China
  • Research Site
    Zhengzhou, China
  • Research Site
    Zhuhai, China
08

References and documents

Individual participant data

Plan to share: Yes — Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal Vivli.org. All requests will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure. 'Yes' , indicates that AZ are accepting requests for IPD, but this does not mean all requests will be approved.

Time frame: AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA PhRMA Data Sharing Principles. For details of our timelines, please rerefer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

Access criteria: When a request has been approved AstraZeneca will provide access to the anonymized individual patient-level data via secure research environment Vivli.org. Signed Data Usage Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information.

Data sharing details ↗ · vivli.org

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Nov 2024 to primary completion in Sep 2026, 21 months.

Of 90 industry-sponsored observational studies under Asthma, half reached primary completion within 27 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 58. This study's 21 months is below that.

Counting every sponsor, half of 456 studies reached it within 36 months; a quarter within 18 and three quarters within 82.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 12, 2024
First posted
Sep 20, 2024
StartActual
Nov 14, 2024
Primary completionActual
Sep 1, 2026
CompletionActual
Sep 1, 2026
Last update
Oct 20, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Active, not recruiting→Completed
changed Oct 20, 2026
Sites
1 site removed
Show 1 removed
  • Research Site · Hohhot, China
Oct 20, 2026
Primary completion
Sep 30, 2026→Sep 1, 2026 (actual)
Oct 20, 2026
Study completion
Sep 30, 2026→Sep 1, 2026 (actual)
Oct 20, 2026
Show all 1 update
  1. Oct 20, 2026
    Active, not recruiting→Completed
    1 site removed
    Show 1 removed
    • Research Site · Hohhot, China
    Primary completion Sep 30, 2026→Sep 1, 2026 (now actual)
    Study completion Sep 30, 2026→Sep 1, 2026 (now actual)
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06605885
Lead sponsor
AstraZeneca
Responsible party
Sponsor
First posted
Sep 20, 2024
Start date
Nov 14, 2024
Primary completion
Sep 1, 2026
Completion
Sep 1, 2026
Last update
Oct 20, 2026

Study contacts

YuBiao Guo
principal investigator · Fifth Affiliated Hospital, Sun Yat-Sen University

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion